ClinicalTrials.gg
RecruitingNCT06488573PROTECTION-BDUpdated Mar 2, 2026

PROgram To Enhance Cardiovascular Risk Trough an Intervention of Nutrition in Bipolar Disorder

An interventional study of Nutritional intervention in Bipolar Depression and Bipolar Disorder (BD), sponsored by University of Sao Paulo. Recruiting at 1 site in Brazil. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-03-02.

Sponsored by University of Sao Paulo · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Bipolar Disorder by University of Sao Paulo — 3 open to participants now, 4 under way, 1 of them phase 3. Bipolar Disorder · University of Sao Paulo.

Planned enrollment
4th of 13
88 · median 60
Started
2026
with 2 others
No phase
7 of 15
2 open now
Registered
13th of 15
by date

Among the 15 studies in Bipolar Disorder by University of Sao Paulo, this one is the 4th largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 with no phase, and was the 13th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

3 of the 15 studies in Bipolar Disorder by University of Sao Paulo are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Bipolar Disorder by University of Sao Paulo, or all of them as a file.
02

Study summary

Individuals with Bipolar Disorder (BD) have twice the risk of being affected by metabolic comorbidities and a 1.8-fold increased risk of mortality from cardiovascular diseases when compared to the general population. These factors are fundamental in the 14-year reduction in the life expectancy of people with TB reported in recent meta-analyses. This occurs mainly due to the increased inflammation associated with the disease, the adverse effects of pharmacological treatments and unhealthy lifestyle habits that are more common in people diagnosed with BD. Nutrition has been studied as an adjunctive treatment in other psychiatric disorders, but there is a lack of studies about the role of nutrition in TB. Considering that diet can impact metabolic health, this randomized controlled study aims to evaluate the effect of a nutritional intervention on cardiovascular risk in patients with TB. The intervention is based on the dietary pattern recommended in the Dietary Guidelines for the Brazilian Population and will be applied by a registered dietitian. According to the literature, the sample size will be 72 individuals with TB (36 in the control group with usual treatment + 36 in the intervention group added to the usual treatment). The intervention will be carried out in 7 individual sessions and 8 group sessions with specific themes. The primary aim of this protocol will be an intervention to contribute to cardiovascular health - verified by serum markers, anthropometric measurements and the Framingham Cardiovascular Risk Score (algorithm used to estimate an individual's 10-year cardiovascular risk). The secondary stages will be the adherence of the intervention and the impact on the quality of life of the participants. The possible positive results of this nutritional intervention can open new clinical perspectives. Meaning that might show that better food choices can protect the cardiovascular health of individuals with TB, leading to a reduction in morbidity and mortality associated with the disease.

03

Conditions studied

  • Bipolar Depression
  • Bipolar Disorder (BD)

Browse trials for

Keywords

  • nutrition intervention
  • nutritional psychiatry
  • bipolar disorder
  • dietary intervention
  • brazilian dietary guideline
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Bipolar disorder types I and II diagnosis
  • Adults of both genders, from 18 to 60 years old
  • In typical pharmacotherapy for BD, for at least one month
  • Agreement to participate in the study with signature of the consent form

Exclusion criteria

Exclusion Criteria:

  • Patients with "very good or excellent" diet quality assessed by the diet quality scale (ESQUADA): >275 out of a score of 375
  • Patients in a state of hypomania or mania: score >8 (Young Mania Rating Scale - YMRS)
  • Patients with severe depression >21 Montgomery-Åsberg Depression Rating Scale
  • Patients at low cardiovascular risk (\<7 points for men or \<9 points for women on the Framingham Global Risk Score)
  • Low weight or eutrophic : \<25kg/m² as in similar studies
  • Pregnant or breastfeeding women
  • Patients diagnosed with anorexia and bulimia nervosa
  • Patientes diagnosed with Irritable Bowl Syndrome or other diagnosed conditions that affect the gastrointestinal function
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • No intervention
    Treatment as usual

    Treatment as usual

  • Experimental
    Nutritional intervention

    Nutritional intervention based on the Brazilian Dietary Guidelines

    Behavioral: Nutritional intervention

Interventions

  • BehavioralNutritional intervention

    7 individual sessions (online) + 6 small group sessions (1-in person + 5 online)

06

What researchers measure

Primary outcomes

  1. C reactive protein

    C reactive protein

    Time frame: Baseline, week 12, week 24 and follow up at week 52

  2. Total cholesterol and fractions

    Total cholesterol and fractions

    Time frame: Baseline, week 12, week 24 and follow up at week 52

  3. Glycemia

    Glycemia

    Time frame: Baseline, week 12, week 24 and follow up at week 52

  4. Glycated hemoglobin A1C

    Glycated hemoglobin A1C

    Time frame: Baseline, week 12, week 24 and follow up at week 52

  5. Triglycerides

    Triglycerides

    Time frame: Baseline, week 12, week 24 and follow up at week 52

  6. HOMA IR

    HOME IR

    Time frame: Baseline, week 12, week 24 and follow up at week 52

  7. Apoliporpotein B

    Apoliporpotein B

    Time frame: Baseline, week 12, week 24 and follow up at week 52

  8. Cardiovascular risk

    Framingham Global Risk Score (-3 to 21; higher scores mean worse outcome)

    Time frame: Baseline, week 12, week 24 and follow up at week 52

  9. Body weight

    Body weight

    Time frame: Baseline, week 12, week 24 and follow up at week 52

  10. Body fat percentage

    Body fat percentage

    Time frame: Baseline, week 12, week 24 and follow up at week 52

  11. waist circumference

    waist circumference

    Time frame: Baseline, week 12, week 24 and follow up at week 52

Secondary outcomes

  1. Dietary assessment - dietary intake

    3-day food record from last week (calories and macronutrients)

    Time frame: Baseline, week 12, week 24 and follow up at week 52

  2. Dietary assessment - dietary quality

    ESQUADA (0-375; higher scores mean better outcome)

    Time frame: Baseline, week 12, week 24 and follow up at week 52

  3. Dietary assessment - dietary adehrence

    NUTRINET (0-72; higher scores mean worse outcome)

    Time frame: Baseline, week 12, week 24 and follow up at week 52

  4. Quality of life WHOQOL

    WHOQOL Bref Portuguese (0-100; higher scores mean better outcome)

    Time frame: Baseline, week 12, week 24 and follow up at week 52

07

Study locations

1 of 1 sites recruiting
  • Fernanda Gabriel
    São Paulo, São Paulo 04514102, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Nov 2026, 7 months later.

Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 7 months is below that.

Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2024
First posted
Jul 5, 2024
StartEst.
Apr 2026
Primary completionEst.
Nov 2026
CompletionEst.
Dec 2027
Last update
Mar 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06488573
Collaborators
Deakin University
Responsible party
Beny Lafer (Associated professor, University of Sao Paulo) — Principal investigator
First posted
Jul 5, 2024
Start date
Apr 2026 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion